Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Amortization of Deferred Charges (2016 - 2022)

Medifast (MED) has disclosed Amortization of Deferred Charges for 5 consecutive years, with $3000.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Amortization of Deferred Charges changed N/A year-over-year to $3000.0, compared with a TTM value of $3000.0 through Mar 2023, down 99.27%, and an annual FY2022 reading of $14000.0, down 84.27% over the prior year.
  • Amortization of Deferred Charges was $3000.0 for Q2 2022 at Medifast, down from $11000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $153000.0 in Q1 2018 and bottomed at $3000.0 in Q2 2022.
  • Average Amortization of Deferred Charges over 3 years is $102000.0, with a median of $136000.0 recorded in 2018.
  • Peak annual rise in Amortization of Deferred Charges hit 12.18% in 2018, while the deepest fall reached 21.39% in 2018.
  • Year by year, Amortization of Deferred Charges stood at $137000.0 in 2018, then decreased by 5.84% to $129000.0 in 2019, then plummeted by 97.67% to $3000.0 in 2022.
  • Business Quant data shows Amortization of Deferred Charges for MED at $3000.0 in Q2 2022, $11000.0 in Q1 2022, and $129000.0 in Q1 2019.